New DBS method slashes targeting errors by 72%, making treatment more precise and accessible for epilepsy, Tourette's, and consciousness disorders. Why it matters: Fewer side effects, better outcomes, and broader access, especially in resource-limited settings. #NeuroTech #DBS Full Study: pubmed.ncbi.nlm.nih.gov/39126726